Table 2.
Incidence of treatment-emergent AEs reported for ⩾5% of patients.
| n (%) | Placebo (n = 64) | PR-fampridine (n = 68) |
|---|---|---|
| No. of patients with AE | 49 (77) | 51 (75) |
| No. of patients with SAE | 5 (8) | 2 (3) |
| AEs | ||
| Nasopharyngitis | 9 (14) | 11 (16) |
| Urinary tract infection | 12 (19) | 6 (9) |
| Back pain | 3 (5) | 6 (9) |
| Balance disorder | 1 (2) | 6 (9) |
| Headache | 5 (8) | 5 (7) |
| Gait disturbance | 2 (3) | 5 (7) |
| Fall | 8 (13) | 4 (6) |
| Arthralgia | 4 (6) | 4 (6) |
| Fatigue | 4 (6) | 4 (6) |
| Nausea | 3 (5) | 4 (6) |
| Dizziness | 1 (2) | 4 (6) |
| MS relapse | 3 (5) | 3 (4) |
| Influenza | 4 (6) | 2 (3) |
| Muscle spasms | 3 (5) | 1 (1) |
AE: adverse event; PR: prolonged-release; SAE: serious adverse event.